A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study

@inproceedings{ORiordan2018ACO,
  title={A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study},
  author={William D. O’Riordan and Alison McManus and Juri Teras and Ivan Poromanski and Maria Cruz-Saldariagga and Megan Quintas and Laura E. Lawrence and ShuJui Liang and Sue Cammarata and Gustavo Jorge Chaparro and Natalia Elizabeth Frassone and Graciana I. Morera and Ant{\^o}nio Tarcisio de Faria Freire and J{\'u}lio C{\'e}sar Stobbe and Rossen Dimov and Borislav Tzvetanov Ninov and Petar Rusev and Simeon Simeonov and Georgi Todorov and Jorge Manuel Perez Godoy and Jaak Lind and Andres Tein and J{\"u}ri Teras and Andrei Uksov and Roland Akhalaia and Erekle Gotsadze and Kakhaber Kashibadze and Jano Vashadze and Katalin Egyud and Zsolt Horv{\'a}th and Lajos Kem{\'e}ny and Levente K{\"o}v{\'a}g{\'o} and Tibor Ol{\'a}h and Yong Kyun Cho and Seong-Ho Choi and Won Seok Choi and Yong Pill Chong and Min Ja Kim and Shin-Woo Kim and Yeon Sook Kim and Jānis Gardovskis and Viktors Lovcinovskis and Maris Nalivaiko and Guntars Pupelis and Eduardo Rodriguez Noriega and Nora Patricia Quintero P{\'e}rez and Adri{\'a}n Camacho Ortiz and Eugen Gutu and Sergiu Revencu and Sergiu Ungureanu and Luis A Camacho Cosavalente and Jaime Ismael Soria Medina and Maria Edelmira Cruz and Oscar Guillermo Pamo Reyna and Pedro Esteban Legua Leiva and Marius Eugen Ciurea and Ion Florea and Carmen Giuglea and Silviu Adrian Marinescu and Silviu Horia Morariu and Remus Ioan Orasan and Petrisor Zorin Crainiceanu and Yen-Hsu Chen and Yin-Ching Chuang and Sinikka Liisa Green and Jeffrey K Kingsley and Loren G. Miller and Robert Houghton and Verne Leroy Willits and Steven Hugh Mannis and Sheri Stucke and Peter A Rives and Eric F. Hansen and Pietro Giuseppe Pecci and Hermilito L Villar and Richard Beasley and P. Augustinus Giordano and J. Barrett Pullman and C. P. Wan and S. Inayat Ali Shah and Godson I Oguchi and Thomas M Birch and Sadi M Dar and Barr L Baynton and Melanie Hoppers},
  booktitle={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2018}
}
Background Delafloxacin is an intravenous (IV)/oral anionic fluoroquinolone with activity against gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]), gram-negative, atypical, and anaerobic organisms. It is approved in the United States for acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible gram-positive and gram-negative organisms, and is in development for the treatment of community-acquired bacterial pneumonia. Methods A… CONTINUE READING
Tweets
This paper has been referenced on Twitter 22 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

and Drug Administration

  • US Foo
  • . Summary basis of approval – BaxdelaTM…
  • 2018
1 Excerpt

Assessment of phototoxicity potential of delafloxacin in healthy male and female subjects: a phase 1 study [abstract F-1198a

  • J Ferguson, L Lawrence, S Paulson
  • Interscience Conference on Antimicrobial Agents…
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…